八珍汤对血虚小鼠红细胞免疫功能作用的实验研究

目的:探讨八珍汤对血虚小鼠红细胞免疫功能的影响.方法:采用失血法制造小鼠血虚模型,失血24h后再取血测定血红蛋白(Hb)含量、及红细胞(RBC)计数及测RBC.c3bR与RBC.ICR值并随即灌胃给八珍汤(20mg/kg.d-1),连续7d,于第8天采血分别测定Hb含量、RBC计数、红细胞c3b受体花环率(RBC.c3bR)及循环免疫复合物花环率(RBC.ICR).结果:①失血后的小鼠,Hb含量、RBC计数及RBC.c3bR均显著低于失血前水平(P＜0.01);而RBC.ICR则显著高于失血前水平(P＜0.01);②八珍汤治疗后,血虚小鼠的Hb、RBC及RBC.c3bR水平提高至接近失血前水平,与生理盐水(NS)对照组比较,均P＜0.01;同时八珍汤具有明显降低血虚小鼠的RBC.ICR的作用,与NS组比较,P＜0.01.结论:①血虚小鼠的红细胞免疫功能呈明显低下状态;②古方八珍汤具有一定补血及恢复红细胞免疫功能的作用.     

电话传送心电图监测与常规心电图诊断心肌缺血的应用比较

目的：探讨电话传送心电图检测（Ｔｒａｎｓｔｅｌｅｐｏｍｉｃ Ｅｌｅｃｔｒｏｃａｒｄｉｏｇｒａｐｈｉｃ Ｍｏｎｉｔｏｒｉｎｇ,ＴＴＭ）心肌缺血的诊断价值。方法：同步检测９７例心肌缺血患者的常规心电图（ＥＣＧ）、电话传送心电图（ＴＴＭ）,调整后者的监测电极与ＥＣＧ的电极部位完全相同,判断二者的Ｓ－Ｔ、Ｔ缺血变化。结果：ＥＣＧ发现９７例典型Ｓ－Ｔ、Ｔ心肌缺血患者,ＴＴＭ有９０例相同变化（敏感性９２．５％     

肝脏螺旋CT多期扫描中造影剂的应用

目的:研究肝脏螺旋CT多期扫描中造影剂的不同注射速度对正常肝脏强化的影响,选择最佳的多期扫描延迟时间.方法:正常肝脏60例随机分为3组,先进行全肝平扫,然后以不同速度(2,3及4s)从肘静脉注入60%泛影葡胺100ml后15s,选择第一肝门层面开始扫描,以后每隔5s在同一层面扫描一次,共扫描3min.分别测量各组腹主动脉、门静脉和肝实质增强前、后不同时间的CT值,其中腹主动脉选取中心部位测量,门静脉选取门静脉主干中心部位测量,肝实质则选三个点(左叶一点,右叶前、后段各一点),然后取平均值.观察3组增强效果并进行统计学比较.结果:各组主动脉、门静脉和肝实质增强效果以3ml/s与4ml/s组为优,4ml/s组略高于3ml/s组,统计学处理两者间无显著性差异(P＞0.05),而与2ml/s组比较均有显著性差异(P＜0.01).2ml/s组主动脉、门静脉及肝实质到达峰值的时间分别为45,70,70,120s开始进入平衡期;3ml/s和4ml/s组均为21,62,62,120s开始进入平衡期.结论:在造影剂总量相同时,适合肝脏螺旋CT多期扫描的造影剂注射速度是3ml/s;最佳的肝脏螺旋CT多期扫描延迟时间为动脉期20s,门静脉期60s,平衡期180s.     

原发性肝癌合并门静脉癌栓的外科治疗(附28例分析)

目的：探讨肝癌合并门静脉癌栓（ＴＴＰＶ）的有效治疗方法。方法：将２８例肝癌合并门静脉主干／主支癌栓患者分３组。１０例行肚切除＋门静脉取栓＋肝动脉、门静脉双灌注化疗栓塞及生物治疗（Ａ组）;１２例行肝动脉、门静脉双灌注化疗栓塞及生物治疗（Ｂ组）;６例行肝动物灌职栓塞（Ｃ组）。结果：Ａ组效果最优,１、２年生存率均为１００％,３年生存率５０％,４年生存率２０％,５年生存率１０％,Ｂ组１年自下而上率为５８．     

阿霉素对实验兔心功能及心肌细胞内游离钙浓度的影响

目的探讨阿霉素慢性心功能听凭的病理生理机制。方法 实验兔每周注射阿霉素１次,,共８周。停药３周后分别测体重（ＢＷ）、心室重量（ＶＷ）、颈动脉压（ＢＰ）、颈动脉平均压（ＭＡＰ）、左心室收缩压（ＬＶＳＰ）、左心室舒张压ＬＶＤＰ）、心输出量（ＣＯ）、心肌细胞胞浆内游离钙浓度,并与健康同龄兔对照。结果 用药后实验组ＶＷ、ＢＷ低于对照组,ＶＷ／ＢＷ高于对照组。ＣＯ、ＢＰ、ＭＡＰ、ＬＶＳＰ均低于对照组,而ＬＶ     

牙周治疗对根除胃内幽门螺杆菌感染的影响

目的探讨控制口腔牙菌斑对根除胃内幽门螺杆菌再复发的作用.方法对80例确诊为幽门螺杆菌感染的胃、十二指肠疾病患者进行口腔卫生指数调查,并随机分成4组进行治疗观察,在治疗停药后1个月、6个月分别进行胃镜复查,观察胃内幽门螺杆菌感染的根除疗效.结果 80例幽门螺杆菌感染的患者口腔卫生状况较差,多属中、重度牙周炎.铋三联疗法配以周密牙周治疗组与单纯三联疗法组,近期胃内幽门螺杆菌根除效果无显著性差异(P>0.05),但在治疗停药半年后,铋三联配以牙周治疗组幽门螺杆菌感染复发率明显低于单纯铋三联治疗组(P<0.05).结论铋三联疗法配以周密牙周治疗,治疗胃、十二指肠疾病中幽门螺杆菌感染,是防止胃内幽门螺杆菌再复发的重要手段.     

Efficacy and Mechanism of Intravenous Sotalol for Termination of Paroxysmal Supraventricular Tachycardia

ＳＶＴ ,ｉｎｃｌｕｄｉｎｇＡＶＲＴａｎｄＡＶＮＲＴ ,ｉｓａｋｉｎｄｏｆａｒｒｈｙｔｈｍｉａｏｆｔｅｎｓｅｅｎｉｎｃｌｉｎｉｃａｌｐｒａｃ ｔｉｃｅ .Ｓｏｔａｌｏｌ,ａｃｌａｓｓⅢａｎｔｉ ａｒｒｈｙｔｈｍｉｃｄｒｕｇｗｉｔｈａｄｄｉｔｉｏｎａｌβ ｂｌｏｃｋｉｎｇａｇｅｎｔｐｒｏｐｅｒｔｉｅｓ ,ｈａｓｂｅｅｎｗｉｄｅｌｙｕｓｅｄｔｏｔｒｅａｔｖａｒｉｏｕｓａｒｒｈｙｔｈｍｉａ(ｓｕｐｒａ ｖｅｎｔｒｉｃｕｌａｒａｎｄｖｅｎｔｒｉｃｕｌａｒ)ｅｆｆｉｃｉｅｎｔｌｙｉｎｗｅｓｔｅｒｎｃｏｕｎｔｒｉｅｓ[1 9]…     

冠脉循环中血小板活化状态对冠心病致病作用的研究

目的：探讨冠脉循环中血小板活化状态在冠心病（ＣＨＤ）发病学中的意义。方法：用放免等方法对受试冠状静脉窦（ＣＳ）及升主动脉（ＡＯ）血行血小板膜表面α－颗粒膜蛋白（α－ＧＭＰ－１４０）和循环内皮细胞（ＣＥＣ）等测定。结果：ＣＨＤ患冠脉循环中α－ＧＭＰ－１４０含量和ＣＥＣ浓度均明显升高（Ｐ〈０．０１）,以急心肌梗塞（ＡＭＩ）组为明显,冠脉狭窄愈严重,二升高愈明显,病灶多发比单发升高明显。结论：ＣＨＤ患冠脉循环中血小板高度激活,在ＣＨＤ的发生发展中有一定的意义。     

Differences in incidence and fatality of COVID-19 by SARS-CoV-2 Omicron variant versus Delta variant in relation to vaccine coverage: A world-wide review

We aim to evaluate the evolution differences in the incidence and case fatality rate (CFR) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta and Omicron variants. The average incidence and CFRs were described between different countries. A gamma generalized linear mixed model (GLMM) was used to compare the CFRs of Delta and Omicron variants based on vaccination coverage. Totally, 50 countries were included for analyses. The incidence of coronavirus disease 2019 (COVID-19) ranged from 0.16/100,000 to 82.95/100,000 during the Delta period and 0.03/100,000 to 440.88/100,000 during the Omicron period. The median CFRs were 8.56 (interquartile range [IQR]: 4.76–18.39) during the Delta period and 3.04 (IQR: 1.87–7.48) during the Omicron period, respectively. A total of 47 out of 50 countries showed decreased CFRs of the Omicron variant with the rate ratio ranging from 0.02 (95% confidence interval [CI]: 0.01–0.03) (in Cambodia) to 0.97 (95% CI: 0.87–1.08) (in Ireland). Gamma GLMM analysis showed that the decreased CFR was largely a result of the decreased pathogenicity of Omicron besides the increased vaccination coverage. The Omicron variant shows a higher incidence but a lower CFR around the world as a whole, which is mainly a result of the decreased pathogenicity by SARS-CoV-2's mutation, while the vaccination against SARS-CoV-2 still acts as a valuable measure in preventing people from death.     

Decreased frequency of a novel T-lymphocyte subset,CD3+CD4−CD7+CD57− T cells,in hepatitis B virus-related end-stage liver disease might contribute to disease progression

CD7 and CD57 are related to the differentiation and functional stages of CD8⁺ T cells. However, the role of their combined presence in CD8⁺ T cells in patients with chronic hepatitis B virus (HBV) infection, especially those with end-stage liver disease, remains unclear. Blood samples from healthy volunteers and patients with chronic hepatitis B were analyzed via Luminex assay and ELISA to measure plasma cytokine levels. Further, recombinant IL-22 was used to stimulate peripheral blood mononuclear cells from healthy volunteers, and the frequency of CD3⁺CD4⁻CD7⁺CD57⁻ T cells and apoptosis rates were investigated via flow cytometry. Patients with end-stage liver disease, particularly those with acute to chronic liver failure, showed decreased CD3⁺CD4⁻CD7⁺CD57⁻ T cell frequency. Furthermore, the prevalence of CD3⁺CD4⁻CD7⁺CD57⁻ T cells was negatively correlated with disease severity, prognosis, and complications (ascites). We also observed that IL-22 promoted apoptosis and brought about a decrease in the number of CD3⁺CD4⁻CD7⁺CD57⁻ T cells in a dose-dependent manner. CD3⁺CD4⁻CD7⁺CD57⁻ T cells displayed a B and T lymphocyte attenuator (BTLA)^highCD25^highCD127^high immunosuppressive phenotype and showed low interferon-γ, tumor necrosis factor-α, granzyme A, and perforin expression levels. The present findings will elucidate the pathogenesis of HBV-related end-stage liver disease and aid the identification of novel drug targets.